- Geron (GERN) shareholders get great news for imetelstat in myelofibrosis.
- Overall response rate: 44%.
- CRs: 4
- PRs: 1
- From the research abstract: "The observed morphologic and molecular remissions confirm selective anti-clonal activity, which has thus far eluded other drugs in MF, including JAK inhibitors. The association between response and spliceosome mutations suggests a broader application for the drug in myeloid malignancies."
- GERN +93% premarket
Geron nearly doubles in premarket trading on imetelstat data
Nov 7 2013, 09:22 ET